Assessing the MGMT status in glioblastoma: one step forward, two steps back?

Assessing the MGMT status in glioblastoma: one step forward, two steps back?

O 6-methylguanin-DNA-methyltransferase (MGMT) would undoubtedly be the molecule of the decade in the field of glioblastoma. More than 15 years ago, the first reports indicated that high activity of this protein in glioma tissue was associated with limited benefit from alkylating-agent chemotherapy, at that time largely nitrosoureas 1. In 2000, methylation of the promoter region of the MGMT gene...

Two steps forward, one step back.

Participants at a community health information network in Glens Falls, N.Y., have come face-to-face with obstacles that could have meant the end to this rural health network that the New York Department of Health and the John A. Hartford Foundation helped launch more than two years ago. Instead, John Laliberte, Glens Falls Hospital's director of information systems, and the rest of the IS team ...

One step forward, two steps back.

Prior research on child poverty has focused heavily on the roles of family structure and, to a lesser extent, parental work patterns to explain trends over time and differences across groups. However, immigrant child poverty has increased significantly over the past three decades even though labor force participation is high among immigrants and immigrant families are likely to be headed by a m...

One step forward and two steps back.

Mesenchymal stem cell therapy: Two steps forward, one step back.

Mesenchymal stem cell (MSC) therapy is poised to establish a new clinical paradigm; however, recent trials have produced mixed results. Although MSC were originally considered to treat connective tissue defects, preclinical studies revealed potent immunomodulatory properties that prompted the use of MSC to treat numerous inflammatory conditions. Unfortunately, although clinical trials have met ...